Intellia Therapeutics, based in Cambridge, Massachusetts, develops CRISPR/Cas9-based therapeutics for high unmet medical needs, including treatments for ATTR amyloidosis and hereditary angioedema. The company went public on May 6, 2016.
Jesse Goodman sold 1,547 shares of NTLA on 1 July at $9.23 per share, worth a total of $14K. They now own 24,359 NTLA shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
